Salus et Vita

Vol. 1 No. 2 (2025)
Articles

Particle Therapy in Cancer Treatment: A Paradigm-Shifting Advancement in Radiotherapy

pdf (Spanish)
  • Brigitte Peiger,
  • Carola Lütgendorf-Caucig
Brigitte Peiger
MedAustron Center for Ion Therapy, Marie-Curie Strasse 5, Wiener Neustadt 2700, Austria
Carola Lütgendorf-Caucig
MedAustron Center for Ion Therapy, Marie-Curie Strasse 5, Wiener Neustadt 2700, Austria

Published 2026-02-05

https://doi.org/10.63975/sev.46

Keywords

  • Particle therapy,
  • Proton therapy,
  • Carbon ions,
  • Bragg peak,
  • Radiotherapy,
  • Radioresistant tumors
    • ...More
    Less

Downloads

Download data is not yet available.

How to Cite

Peiger, B., & Lütgendorf-Caucig, C. (2026). Particle Therapy in Cancer Treatment: A Paradigm-Shifting Advancement in Radiotherapy. Salus Et Vita, 1(2), 12-14. https://doi.org/10.63975/sev.46
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Abstract

Particle therapy constitutes a major advance in contemporary oncology by enabling highly precise radiation delivery using protons and carbon ions. Unlike conventional radiotherapy, its physical advantages—particularly the Bragg peak—allow maximal dose deposition within the tumor while significantly reducing exposure to surrounding healthy tissues. This improves local control and decreases acute and late toxicities, especially in tumors near critical structures or with marked radioresistance. Clinical experience in specialized centers, such as MedAustron and CNAO, has shown favorable outcomes in pediatric and adult populations, including cases requiring re-irradiation. Emerging modalities such as helium ion therapy may offer intermediate radiobiological benefits, though further clinical validation is needed. Persistent challenges include limited availability worldwide and the need for stronger comparative evidence. Overall, particle therapy broadens therapeutic possibilities and strengthens the future of precision oncology.

pdf (Spanish)

References

  1. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun;26(3):211–8.
  2. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021 Aug 12;9:20503121211034370.
  3. Randi G, Zaro F, Carvalho RN, Martos C, Dimitrova N, Dyba T, et al. The European Cancer Information System (ECIS) web application.
  4. Giusti F, Martos C, Trama A, Bettio M, Sanvisens A, Audisio R, et al. Cancer treatment data available in European cancer registries: Where are we and where are we going? Front Oncol. 2023 Feb 8;13:1109978.
  5. Kato S, Ohno T, Tsujii H, Nakano T, Mizoe JE, Kamada T, et al. Dose escalation study of carbon ion radiotherapy for locally advanced carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):388–97.
  6. Grau C, Dasu A, Troost EGC, Haustermans K, Weber DC, Langendijk JA, et al. Towards a European prospective data registry for particle therapy. Radiother Oncol. 2024 Jul;196:110293.
  7. Matsumoto Y, Fukumitsu N, Ishikawa H, Nakai K, Sakurai H. A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. J Pers Med. 2021 Aug 23;11(8):825.
  8. Zschaeck S, Falk M, Löck S, Troost E, Stützer K, Wohlfahrt P, et al. PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): Study protocol for a randomised controlled trial. Trials. 2016 Nov 15;17.
  9. Wilson JS, Main C, Thorp N, Taylor RE, Majothi S, Kearns PR, et al. The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review. J Neurooncol. 2024 Mar;167(1):1–34.
  10. Stock M, Georg P, Mayer R, Böhlen TT, Vatnitsky S. Development of Clinical Programs for Carbon Ion Beam Therapy at MedAustron. Int J Part Ther. 2016;2(3):474–7.
  11. Penescu LC, Landscapes A. The Beam Quality Assurance of the MedAustron Particle Therapy Accelerator. 2017.
  12. Pivi MTF, Franco AD, Farinon F, Kronberger M, Kurfuerst C, Kurfürst C, et al. Overview and Status of the MedAustron Ion Therapy Center Accelerator. 2017.
  13. Breen WG, Geno CS, Waddle MR, Qian J, Harmsen WS, Burns TC, et al. Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis. Neurooncol Adv. 2024 Dec;6(1):vdae034.
  14. Kiseleva V, Gordon K, Vishnyakova P, Gantsova E, Elchaninov A, Fatkhudinov T. Particle Therapy: Clinical Applications and Biological Effects. Life (Basel). 2022 Dec 9;12(12):2071.
  15. Orlandi E, Barcellini A, Vischioni B, Fiore MR, Vitolo V, Iannalfi A, et al. The Role of Carbon Ion Therapy in the Changing Oncology Landscape-A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological Hadrontherapy. Cancers (Basel). 2023 Oct 20;15(20):5068.
  16. Koosha F, Ahmadikamalabadi M, Mohammadi M. Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma. Advances in Radiation Oncology. 2024 May 1;9(5). Available from: https://www.advancesradonc.org/article/S2452-1094(24)00028-9/fulltext
  17. Hrbacek J, Kacperek A, Beenakker JWM, Mortimer L, Denker A, Mazal A, et al. PTCOG Ocular Statement: Expert Summary of Current Practices and Future Developments in Ocular Proton Therapy. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1307–25.
  18. Mairani A, Mein S, Blakely E, Debus J, Durante M, Ferrari A, et al. Roadmap: helium ion therapy. Phys Med Biol. 2022 Aug 5;67(15).
  19. Wickert R, Tessonnier T, Deng M, Adeberg S, Seidensaal K, Hoeltgen L, et al. Radiotherapy with Helium Ions Has the Potential to Improve Both Endocrine and Neurocognitive Outcome in Pediatric Patients with Ependymoma. Cancers (Basel). 2022 Nov 28;14(23):5865.